Aprea Therapeutics stockholders elect three Class II directors, ratify EisnerAmper as auditor

Aprea Therapeutics, Inc.

Quorum of 70.46% represented at June 20, 2024 annual meeting.
Michael Grissinger, Gabriela Gruia, Rifat Pamukcu elected as Class II directors with >3M votes each vs. ~55K withheld.
Ratification of EisnerAmper LLP as auditor approved: 3,788,888 for, 7,750 against, 29,541 abstain.
Broker non-votes of 719,524 on director elections; none on ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.